• Alector to Participate in Upcoming Healthcare Conferences

    Source: Nasdaq GlobeNewswire / 25 Feb 2025 08:00:00   America/New_York

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

    • TD Cowen 45th Annual Health Care Conference (Boston, Massachusetts)
      • Tuesday, March 4, 2025, at 9:10 a.m. ET, corporate presentation
    • Leerink Partners Global Biopharma Conference (Miami, Florida)
      • Tuesday, March 11, 2025, at 8:40 a.m. ET, corporate presentation
    • Stifel 2025 Virtual CNS Forum
      • Tuesday, March 18, 2025, at 2:00 p.m. ET, corporate presentation

    A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

    About Alector
    Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of genetically-validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer’s disease, Parkinson's disease, and Lewy body dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

    Alector Contacts:
    Alector
    Katie Hogan
    (202) 549-0557
    katie.hogan@alector.com

    Argot Partners (media)
    David Rosen
    (212) 600-1494
    alector@argotpartners.com

    Argot Partners (investors)
    Laura Perry
    (212) 600-1902
    alector@argotpartners.com


    Primary Logo

Share on,